Family History of Primary Liver Cancer Associated with Increased Risk for Extrahepatic CCA

March 2022, Vol 3, No 1

The subtypes of cholangiocarcinoma (CCA), including intrahepatic CCA and extrahepatic CCA, have various underlying tumor microenvironments, pathobiology, epidemiologic features, and risk factors; however, the genetic underpinnings of the CCA subtypes have not been previously defined.

Madhulika Eluri, MD, University of Texas M.D. Anderson Hematology/Oncology Fellowship, Houston, and colleagues conducted a case-control study to determine the correlation between a family history of primary liver cancer and the incidence of CCA in the United States. Dr Eluri presented the results of the study at the 2022 ASCO GI Cancers Symposium.

This study was conducted at M.D. Anderson Cancer Center and included 429 patients with pathologically confirmed CCA and 1075 healthy controls. Of the 429 patients with CCA, 308 patients had intrahepatic CCA and 121 had extrahepatic CCA.

Patients were interviewed regarding their family history of cancer, including the number of relatives with cancer, the type of cancer, the patient’s relationship with the relative, and the age at which the relative was diagnosed with cancer.

Besides hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, having a family history of cancer was significantly associated with intrahepatic CCA (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2-2.2) and extrahepatic CCA (OR, 1.6; 95% CI, 1.1-2.5). The prevalence of family history of primary liver cancer in first-degree members was higher in patients with extrahepatic CCA compared with patients with intrahepatic CCA (6.6% vs 1.6%, respectively). A higher proportion of patients in the extrahepatic CCA cohort had multiple relatives with primary liver cancer compared with the patients in the intrahepatic CCA cohort (4.1% vs 1%, respectively).

Although primary liver cancer in first-degree relatives was significantly associated with extrahepatic CCA (OR, 9.4; 95% CI, 2.9-30.7), no significant association was observed for patients with intrahepatic CCA (OR, 1.7; 95% CI, 0.5-5.9). All estimated ORs were adjusted for age, sex, race, smoking, alcohol, hepatitis virus infection, diabetes, and obesity.

The results of this case-control study indicate that having a family history of primary liver cancer in a first-degree family member is associated with an increased risk for extrahepatic CCA in the United States.

Source

Eluri M, Hatia R, Javle MM, Hassan M. The association of family history of primary liver cancer with cholangiocarcinoma: USA case-control study. Abstract 403.

Related Items

Real-World Outcomes of Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer in the United States: Real-World Insights
March 2026, Vol 7, No 1
A US real-world claims database analysis demonstrated that durvalumab plus gemcitabine and cisplatin improves survival in patients with advanced biliary tract cancer.
Real-World Evidence Confirms Clinical Efficacy of Durvalumab or Pembrolizumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
March 2026, Vol 7, No 1
Real‑world outcomes show survival benefit of first-line durvalumab or pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
Tinengotinib Shows Promise in Overcoming FGFR Inhibitor Resistance in Advanced Cholangiocarcinoma
March 2026, Vol 7, No 1
Tinengotinib, a novel FGFR inhibitor, has the potential to overcome resistance to prior FGFR therapies in the treatment of advanced cholangiocarcinoma.
Zanidatamab Improves Survival Outcomes in HER2-Positive Biliary Tract Cancer: Post-Hoc HERIZON-BTC-01 Analysis
March 2026, Vol 7, No 1
A post-hoc analysis of HERIZON-BTC-01 demonstrates improved survival outcomes in patients utilizing zanidatamab.
Safety and Preliminary Activity of Ivosidenib Plus Durvalumab With Gemcitabine and Cisplatin in IDH1-Mutant Cholangiocarcinoma: Phase 1b/2 Study Results
March 2026, Vol 7, No 1
Ivosidenib in combination with durvalumab plus gemcitabine and cisplatin shows potential activity with minimal toxicity in patients with IDH1‑mutant cholangiocarcinoma.
Treatment Outcomes of IDH1-Mutant Cholangiocarcinoma in the United States: A Real-World Analysis
March 2026, Vol 7, No 1
Real‑world data in IDH1‑mutant cholangiocarcinoma illuminates biomarker testing trends, treatment sequencing, and survival outcomes, outlining the role of ivosidenib in second‑line care.
Adjuvant Sintilimab Plus Capecitabine in Resected Extrahepatic Cholangiocarcinoma: Interim Results From a Phase 2 Study
March 2026, Vol 7, No 1
Adjuvant sintilimab plus capecitabine shows promising recurrence‑free survival and manageable safety in resected extrahepatic cholangiocarcinoma.
Adjuvant Chemoradiation and Immunotherapy for Patients With High-Risk Resectable Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: The ACCORD Trial
March 2025, Vol 6, No 1
The ACCORD trial demonstrated that adjuvant chemoradiation combined with immunotherapy significantly improved survival outcomes in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer compared with observation alone.
Durvalumab Plus Gemcitabine-Based Chemotherapy With or Without Lenvatinib for Advanced Biliary Tract Cancer: A Retrospective Study
March 2025, Vol 6, No 1
A study of patients with advanced biliary tract cancer found that adding lenvatinib to durvalumab and gemcitabine-based chemotherapy improved progression-free survival, objective response rate, and disease control rate.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Profession or Role
Primary Specialty or Disease State